Adverse events · patients with non‐specific acute and subacute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes* · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete resolution of endophthalmitis at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
It is very uncertain whether combined steroid and antibiotic therapy changes complete resolution of endophthalmitis at 3 months' compared with antibiotics alone (very low certainty).
1 finding from 1 review
Visual acuity · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy may leads to higher visual acuity 6/6 to 6/18 at 3 months' compared with antibiotics alone (low certainty).
2 findings from 1 review
Improvement in visual acuity at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraocular pressure ( · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
1 finding from 1 review
Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy showed no clear difference in adverse events at 3 to 12 months' compared with antibiotics alone (low certainty).
1 finding from 1 review
Costs · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking cessation · people who smoke
Fast‐acting nicotine replacement therapy showed no clear difference in smoking cessation compared with nicotine patch (high certainty).
1 finding from 1 review
Overall serious adverse events · people who smoke
1 finding from 1 review
Treatment withdrawal · people who smoke
It is very uncertain whether fast‐acting nicotine replacement therapy changes treatment withdrawals compared with nicotine patch (very low certainty).
1 finding from 1 review
AHI score reduction to below 5 points. · obstructive sleep apnoea
Myofunctional therapy plus nasal washing showed no clear difference in AHI score reduction to below 5 points. compared with nasal washing alone (low certainty).
1 finding from 1 review
AHI score change. · obstructive sleep apnoea
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
1 finding from 1 review
Overall survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found